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Communication between nerve cells is mediated 
by both electrical and chemical signals. Chemical 
neurotransmission can be further categorized into 
fast and slow components. Fast acting neurotrans- 
mitters directly influence neuronal electrical ex- 
citability by binding to cell surface receptors 
which serve as ligand-gated ion channels, thereby 
directly modulating membrane potential and cell 
tivation in the induction of LTP  in CA1 pyramidal 
cells [4]. Infusion of phospho-I1 peptides sub- 
stituted for the requirement for PKA activity in 
LTP induction. Thus, in contrast with LTD, 
which requires PP1 activity, LTP is promoted by 
PP1 inhibition. The physiological role played by 
I1 at the Schaffer collateral/CAl synapse has 
recently been questioned following the examin- 
firing. Neurotransmitter receptors may otherwise ation of I1 knockout mice, which display normal 
modulate neuronal excitability indirectly, by coup- synaptic plasticity at this synapse [S]. This sug- 
ling to intracellular signalling pathways that im- gests that additional neuronal PP1 regulatory 
pact on the functional activity of ligand- and elements may exist. 
voltage-gated ion channels, ion pumps, and the PP1 has been shown to be present at synaptic 
machinery for chemical neurotransmission. These junctions [6] and is specifically enriched in den- 
indirect actions are relatively slow, and often 
involve cascades of protein phosphorylation which 
serve to alter the biochemical activities of substrate 
proteins, and hence cellular physiology. 
Recent work has indicated that protein phos- 
phatase 1 (PPl) is an important component of the 
signalling machinery that controls synaptic trans- 
mission. In the rat hippocampus, pharmacological 
inhibition of protein phosphatase activity prevents 
the induction of long-term depression (LTD) [l], 
a use-dependent decrease in synaptic efficacy that 
may contribute to the process of information 
storage in the brain [2]. Further work used the PPl 
regulatory protein, inhibitor 1 (Il) ,  to show that 
PPl was specifically responsible for this effect. I1 
is converted from an inactive enzyme into a potent 
PPl inhibitor following phosphorylation by 
CAMP-dependent protein kinase A (PKA). When 
phospho-I1 peptides were infused into CAI pyr- 
amidal cells, L T D  induction was blocked [3]. 
Complementary experiments have addressed the 
role of PPl in the induction of long-term potenti- 
ation (LTP). Pharmacological inhibition of phos- 
phatases removed the requirement for PKA ac- 
dritic spines [7] ,  postsynaptic specializations that 
receive the vast majority of excitatory input in the 
brain. Several candidate substrates for PP1 exist at 
the synapse. The phosphorylation state and ac- 
tivity of calcium/calmodulin-dependent protein 
kinase I1 (CaMKII) has been shown to be regu- 
lated by PPl specifically within the postsynaptic 
density compartment [8,9]. CaMKII is an at- 
tractive substrate molecule through which PP1 
might mediate its effects on excitatory synaptic 
transmission. CaMKII has itself been shown to be 
enriched in dendritic spines and exerts a strong 
influence on synaptic efficacy [lo-121. Additional 
potential PP1 substrate molecules that govern 
synaptic plasticity include the N-methyl-D-aspar- 
tate (NMDA) receptor [13], protein kinase C [14], 
and in the nucleus, the cAMP response element- 
binding (CREB) protein [lS]. Thus, PPl plays a 
diverse role in the regulation of neuronal sub- 
strates. In fact, PPl is involved in many different 
cellular processes, including regulation of gene 
expression, cell division cycle, glycogen metab- 
olism, and muscle contraction [16]. How is the 
activity of the enzyme directed specifically to the 
substrates involved in these diverse cellular pro- 
cesses ? The answer to this appears to be that PPl 
is regulated by a family of proteins that are termed 
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Figure I 
Distribution and activity of PP I 
(A) lrnmunoblots showing the relative distribution of the a and y 
isoforms of PP I in rat brain hornogenate fractions. Loading was 
normalized for protein content (50 ,ug/lane). (B) Catalytic activity 
of PPI towards phosphorylase o measured in rat brain horno- 
genate fractions normalized for total protein content. Rat brain 
cortex was lysed by sonication in 50 rnM Tris/HCI (pH 8.0) I20 
rnM NaCI, 0.5% Nonidet P-40, I mM EDTA, I mM PMSF, 
20 &rnI leupeptin/antipain and 5 &rnI pepstatin/chymostatin. 
Hornogenate was centrifuged at I9  000 g for 20 rnin. Soluble and 
particulate suspensions were assayed for PP I activity as described 
previously. 
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cellular localizations. Targeting subunits gener- 
ally bind to PP1 with high affinity and as a result 
dictate the subcellular localization of PP1, thereby 
placing the enzyme in proximity to the substrates 
that are responsible for controlling a given cellular 
process. In addition to dictating localization, 
targeting subunits may also modulate PP1 cata- 
lytic activity toward selected substrates in re- 
sponse to specific intracellular signals [17]. 
Preliminary evidence for the existence of PP1 
targeting proteins in the brain came from cellular 
fractionation studies. Particulate and soluble frac- 
tions of cortical homogenate were separated by 
high-speed centrifugation. The  majority of the 
PP1 catalytic subunit was found in the particulate 
fraction. However, when the catalytic activity of 
PPl  in these two fractions was measured, using 
phosphorylase a as substrate, the majority of the 
activity was found in the soluble fraction (Figure 
1). Purified PPl  is highly soluble. This implies 
that much of the PP1 in cortical homogenate is 
associated with proteins in the insoluble fraction, 
and that this association inhibits the enzyme. 
Isolation and characterization of novel 
PP I -interacting proteins 
Using the a isoform of the catalytic subunit of PP1 
as a bait, a rat brain cDNA library was screened 
using the yeast two-hybrid expression cloning 
system [ 181. Several different clones were identi- 
fied based on restriction enzyme digestion and 
sequence analysis. These included cDNAs for the 
PPl  -binding proteins spinophilin [ 191, phos- 
phatase 1 nuclear targeting subunit (PNUTS) 
[20] and p53BP2 [21]. Of these proteins, spino- 
philin has been most thoroughly characterized: it 
is found in a complex with PP1 in rat brain lysates, 
and is a potent inhibitor of PPl  activity in vitro. 
The name spinophilin is based on the specific 
localization of the protein in the dendritic spine 
compartment, a subcellular organelle in which 
PPl  is also specifically enriched [7]. This localiz- 
ation may be highly significant with respect to the 
role played by PPl in the regulation of synaptic 
plasticity ; dendritic spines are thought to contain 
the signal transduction machinery responsible for 
the regulation of glutamatergic synaptic trans- 
mission. Spinophilin contains a single PDZ do- 
main (Figure 2); this domain is present in many 
cytoskeletal proteins and often serves to mediate 
binding to the terminus of transmembrane pro- 
teins. In the brain, the PSD-95 family of PDZ 
domain-containing proteins has been shown to 
bind to NMDA receptors and Shaker-type K+ 
channels and to promote the clustering of these 
receptors in heterologous cells [22-241. A second 
class of PDZ domain-containing proteins, the 
GRIP/ABP family, binds to the GluR2 glutamate 
Figure 2 
Domain organization of spinophilin 
The N-terminus of the molecule binds to, and can bundle, F-actin. 
The PP I -binding domain lies immediately upstream of the PDZ 
domain. The arnphipathic helix is thoughtto mediate the formation 
of a coiled-coil spinophilin hornodirner. 
pp1 Amphipathic Helix 
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receptor subunit [24]. This implies that spino- 
philin might also be associated with a trans- 
membrane protein, possibly an ion channel or 
neurotransmitter receptor that resides in the spine. 
The  binding site for PPl  has been mapped to a 
position immediately adjacent to the PDZ domain 
[25]. Thus, spinophilin may place PP1 in an 
opportune position to exert its control over sub- 
strates that govern synaptic strength. 
Spinophilin also contains a region predicted 
to form a coiled-coil. Recent two-hybrid analysis 
showed that this region of spinophilin can bind to 
itself, indicating that the molecule may exist as a 
homomultimer in vivo. The amino terminus of 
spinophilin binds to, and will bundle, F-actin [26], 
suggesting that spinophilin is an integral part of 
the dense actin filament network that exists in 
dendritic spines. Scanning of the spinophilin 
sequence for consensus motifs for phosphorylation 
reveals the presence of many potential sites that 
are clustered in the N-terminal actin-binding 
region. Phosphorylation at these sites has the 
potential to alter functional interactions with the 
actin cytoskeleton. In addition, PP1 has been 
implicated in the control of the actin-myosin 
cytoskeleton in non-neuronal cells [27]. This 
suggests that the spinophilin/PPl complex may 
play a role in regulating actin dynamics in the 
spine and thereby control spine morphology and 
turnover. In developing rat cortex, spinophilin 
expression peaks at a time when spines are being 
formed [19,28] and spine structure is thought to 
influence synaptic efficacy [28] ; therefore, modu- 
lation of the cytoskeleton provides a potential 
mechanism for the spinophilin/PPl-mediated 
regulation of synaptic transmission. 
An additional contribution to the synaptic 
targeting of PP1 is probably provided by a protein 
that is related in structure to spinophilin. This 
protein, identified based on its ability to bind to F- 
actin, was named neurabin (neuronal actin binding 
protein) [29]. Neurabin was also found to bind to 
PP1 [26]. Recently, p70 ribosomal S6 kinase was 
shown to bind to the PDZ domain of neurabin 
[30]. This kinase also binds to the PDZ domain of 
spinophilin (P. E. Burnett and P. B. Allen, un- 
published work). These results raise the possi- 
bility that a p70 ribosomal S6 kinase/spinophilin/ 
neurabin/PPl complex may serve to regulate local 
protein synthesis at the synapse. New protein 
synthesis is detected in response to synaptic 
stimulation and may be required for certain forms 
of long term plasticity [31,32]. 
Fine mapping of the PPl  binding site in 
spinophilin revealed that PPl  binds to a motif that 
is found in other PP1 regulatory proteins, namely, 
R/ K- R/ K-Hydrophobic-X- F /W [ 25,3 31. Muta- 
tion of the phenylalanine residue to alanine abol- 
ished the binding of PPl to spinophilin. A short 
peptide encompassing this site does not inhibit 
PP1 activity, but is still capable of binding to PP l ,  
as shown by competition assays with full-length 
spinophilin [25]. When added to immunoprecipi- 
tation reactions, the spinophilin peptide antago- 
nized the interaction with PP1. This antagonist 
peptide was infused into acutely dissociated stri- 
atal neurons in the whole-cell patch clamp mode to 
assess the physiological consequences of disrupt- 
ing the PP1-spinophilin complex [34]. The 
paradigm examined was the time-dependent re- 
duction of ~-amino-3-hydroxy-5-methyl-4-iso- 
xazolepropionic acid (AMPA) current response 
which is seen after patching on to these cells. 
This run-down effect can be prevented by the 
application of a dopamine D1 receptor agonist, 
which is consistent with the observation that 
AMPA responses are potentiated by PKA- 
dependent phosphorylation [35,36]. In addition, 
run-down was prevented by inhibiting protein 
phosphatases with okadaic acid, or by the infusion 
of a PP1 inhibitor, phospho-dopamine and 
CAMP-regulated phosphoprotein (DARPP32) 
peptide [37]. Infusion of the spinophilin an- 
tagonist peptide also prevented the AMPA 
current run-down, and infusion of control 
spinophilin peptide, incorporating the phenyl- 
alanine to alanine mutation that abolishes PPl 
binding to spinophilin, had no effect on run-down. 
These results suggest that spinophilin-mediated 
targeting of PP1 to the AMPA receptor serves to 
maintain the channel in a dephosphorylated, less 
active state. The  channel is stimulated by PKA- 
mediated phosphorylation; PKA simultaneously 
inhibits PP1 activity due to the phosphorylation 
and activation of the PP1 inhibitor, DARPP32. In 
binding to PP1, phospho-DARPP32 presumably 
also displaces PPl from spinophilin and the 
AMPA channel. The  results support the idea that 
spinophilin is a bona fide neuronal PPl targeting 
protein. 
Not all PP1 binding proteins found in the 
nervous system are restricted to dendrites. For 
instance, one of the PP1 interacting proteins 
identified in the yeast two-hybrid screen was 
localized discretely to the cell nucleus, earning this 
protein the acronym PNUTS (phosphatase 1 
nuclear targeting subunit) [20]. PNUTS has a 
very high affinity for PP1 and inhibits catalytic 
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Figure 3 
Domain organization of PNUTS 
NLS, nuclear localization signal consensus motif; SH3, consensus 
for SH3 domain binding; PP I, PP I -binding site; P loop, nucleotide 
binding consensus motif; RGG, Arg/Gly/Gly repeat boxes impli- 
cated in RNA binding; histidine rich, region containing multiple 
imperfect direct repeats. 
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activity with an IC,, in the picomolar range. 
Several motifs can be identified from the predicted 
amino acid sequence that give some clue as to 
possible function (Figure 3). These include the 
expected nuclear localization signal, RGG boxes 
(which are implicated in RNA binding) and a 
putative zinc finger. Given the localization and 
structure of PNUTS it seems possible that it may 
be involved in controlling the established role that 
PP1 plays in regulating gene expression [38]. In 
this way PNUTS-PP1 may contribute to the 
regulation of long-term changes in neuronal ac- 
tivity. 
In the future, it will be of interest to identify 
additional PP1 substrates that are involved in 
neuronal function and to characterize further the 
role played by PPl regulatory subunits in the inte- 
gration of signals that control the postsynaptic 
response. 
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